Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer
Open Access
- 20 August 2019
- journal article
- research article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 11 (5) , 517-522
Abstract
Survival outcome of ovarian suppression plus tamoxifen has been shown to be comparable with chemotherapy in premenopausal women; however, there are a few previous studies that compared this treatment to the current standard adriamycin and cyclophosphamide (AC) regimen. The aim of the present study was to compare the survival outcome of gonadotropin‑releasing hormone (GnRH) agonist plus tamoxifen (GnRH‑TAM) and chemotherapy AC plus tamoxifen (AC‑TAM) in premenopausal patients with early breast cancer who were hormone receptor‑positive. Premenopausal patients with early breast cancer who were treated at The Siriraj Hospital between January 2005 and December 2015 were retrospectively recruited. The inclusion criteria included newly diagnosed breast cancer, size ≤3 cm, node‑negative and hormone receptor‑positive. All patients received adjuvant systemic therapy and were divided into two groups. In the GnRH‑TAM group, the patients received subcutaneous injection of 10.8 mg of goserelin every 3 months for 2‑3 years and TAM (20 mg/day) for 5 years. In the AC‑TAM group, AC was administered every 3 weeks for 4 cycles followed by TAM (20 mg/day) for 5 years. In total, 40 patients received GnRH‑TAM and 130 patients received AC‑TAM. The mean age at diagnosis was 44.4±6.3 years while the median follow up time was 77 (36‑167) months. There was no mortality in either group and no significant difference in disease‑free survival between the two groups. No adverse effect occurred and good compliance was observed in all patients who received GnRH‑TAM. Treatment with GnRH‑TAM resulted in a comparable survival outcome and better quality of life compared with AC‑TAM.Keywords
This publication has 36 references indexed in Scilit:
- Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancerBMC Cancer, 2012
- Do Asian breast cancer patients have poorer survival than their western counterparts? A comparison between Singapore and StockholmBreast Cancer Research, 2009
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93)European Journal of Cancer, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Survival analyses from the ZEBRA studyEuropean Journal of Cancer, 2003
- Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5European Journal of Cancer, 1999
- PP-5-6 Castration and Tamoxifen Versus Chemotherapy (FAC) for Premenopausal, Node and Receptors Positive Breast Cancer Patients: A Randomized Trial with a 7 Years Median Follow UpEuropean Journal of Cancer, 1996
- Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trialEuropean Journal of Cancer, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991